Long known as an uncommon but serious medical disorder requiring medical management, vitamin B 12 deficiency is now seen to be common worldwide, but it is in a quite different form than traditionally envisioned. Most of the newly recognized deficiency is subclinical in nature, its health impact and natural history are uncertain, and its prevalence has been greatly inflated by also including persons with "low-normal" vitamin B 12 levels, few of whom are deficient. The spread of folic acid fortification has also introduced concerns about folate's potentially adverse neurologic consequences in persons with undetected vitamin B 12 deficiency. Fortification with vitamin B 12 may prove more complicated than fortification with folic acid, however, because the bioavailability of vitamin B 12 is limited. Bioavailability for those who need the vitamin B 12 the most is especially poor, because they often have malabsorption affecting either classical intrinsic factor-mediated absorption or food-vitamin B 12 absorption. Moreover, new evidence shows that many elderly persons respond poorly to daily oral doses under 500 μg (1 μg = 0.74 nmol), even if they do not have classical malabsorption, which suggests that proposed fortification with 1 to 10 μg may be ineffective. Those least in need of vitamin B 12 usually have normal absorption and are thus at greatest risk for whatever unknown adverse effects of high-dose fortification might emerge, such as the effects of excess accumulation of cyanocobalamin. Studies are needed to define the still unproven health benefits of vitamin B 12 fortification, the optimal levels of fortification, the stability of such fortification, interactions with other nutrients, and any possible adverse effects on healthy persons. The answers will permit formulation of appropriately informed decisions about mandatory fortification or (because fortification may prove a poor choice) about targeted supplementation in subpopulations with special needs for additional vitamin B 12 , such as vegetarians, nursing mothers, and the elderly.
Introduction
Classical deficiency of vitamin B 12 (more precisely named cobalamin, of which vitamin B 12 , also called cyanocobalamin, is one form) is uncommon, but poses very serious clinical problems of progressive megaloblastic anemia and potentially irreversible neurological abnormalities. Because of that, and its usual origin from gastric or intestinal disease, classical deficiency requires individualized medical response. In the 1980s, the introduction of sensitive and accurate metabolic tests and the identification of subclinical vitamin B 12 deficiency [1] , as well as the recognition that vitamin B 12 deficiency was very common, broadened the concept of deficiency to include purely biochemical changes [2] . Many surveys, including data presented at this WHO Technical Consultation, have established that this mild, biochemical, and typically asymptomatic vitamin B 12 deficiency affects many people, especially the elderly, and occurs worldwide. The concerns about widespread vitamin B 12 deficiency, whatever its degree, have combined with residual worries that mandatory fortification of the diet with folic acid may have adverse neurological consequences for persons with undiagnosed vitamin B 12 deficiency. These led naturally to considerations whether a population-wide approach to preventing or treating undiagnosed vitamin B 12 deficiency is warranted. Discussions of dietary vitamin B 12 fortification have been held [3, 4] , and the topic is S178 R. Carmel now considered at this WHO Technical Consultation. Several background concepts and facts about vitamin B 12 absorption, bioavailability, and deficiency will be presented to provide the necessary context for discussion of vitamin B 12 fortification.
Concepts of vitamin B 12 absorption relevant to fortification Physiological vitamin B 12 absorption is tightly regulated
To an extent unmatched by many other nutrients, including folic acid, vitamin B 12 depends critically on a very tightly regulated transport system. Vitamin B 12 is constantly chaperoned by binding proteins in the stomach, gut, and bloodstream to binder-specific cellular receptors ( fig. 1) . The specificity of the transport and cellular uptake processes assures that this trace vitamin is obtained from its animal-derived food sources. At the same time, the limited capacity of the gastric intrinsic factor (IF)-mediated absorption process, which rarely allows more than 1 to 2 μg (1 μg of vitamin B 12 = 0.74 nmol) of vitamin B 12 to be absorbed at any time [5, 6] , also suggests that unlimited accumulation of vitamin B 12 is somehow undesirable. Perhaps, too high an intracellular content of unused vitamin B 12 or its potential conversion to nonfunctional or harmful analogs (whose entry into cells the specific transport process seems in part meant to prevent) has undesirable consequences.
Nonspecific absorption of excess vitamin B 12 is very limited
Specific IF-mediated absorption is saturable. Its rate varies inversely with the amount ingested, and capac- [53] with permission of the publisher.) Panel 1: Secretion of gastric intrinsic factor (IF), acid, and pepsin and release of vitamin B 12 from food and binding to R binder (also called transcobalamin [TC]-I or haptocorrin). Panel 2: Biliary and pancreatic secretion, and release of vitamin B 12 following degradation of TC-I by pancreatic enzymes. Panel 3: Ileal cell uptake of IF-vitamin B 12 via specific receptor (passive, IF-free diffusion is not shown), followed by intralysosomal release of vitamin B 12 , which is then bound to TC-II and enters the portal circulation. Panel 4: Cellular uptake of TC II-vitamin B 12 throughout the body (e.g., by bone marrow or liver), followed by intracellular release of vitamin B 12 , which is then modified to various vitamin B 12 forms, such as adenosylcobalamin (AdoCbl) or methylcobalamin (MeCbl), and attaches to enzymes; vitamin B 12 carried by TC-I in the bloodstream is not taken up by cells and is not shown in this panel ity is quickly exceeded by supplements [5] [6] [7] . In addition to this specific absorption process, a tiny fraction of vitamin B 12 , usually estimated at 1%, is taken up nonspecifically and linearly by nonsaturable diffusion [5, 6] . How much vitamin B 12 is absorbed by these two processes in any person depends on the amount of vitamin B 12 taken in and how intact the specific absorption process is (table 1) . When IF is absent or its uptake in the ileum is abnormal, absorption can proceed only by limited diffusion [5, 6] .
Binding of vitamin B 12 in food affects its bioavailability
Vitamin B 12 must be released from its binding proteins in food before it can attach to IF ( fig. 1 ) [8] . The process requires acid and pepsin, but other poorly understood factors may play roles as well [8] [9] [10] [11] . When vitamin B 12 release fails, food-vitamin B 12 becomes unavailable for later binding by IF, and food-vitamin B 12 malabsorption results [8] . Free vitamin B 12 , such as in supplements, remains available to IF, however. The degree of limitation of vitamin B 12 absorption in foodvitamin B 12 malabsorption has been poorly quantified. The influence of specific foods on vitamin B 12 assimilation also seems to vary and is not well understood. Milk and vitamin B 12 -fortified cereal provide high vitamin B 12 bioavailability in normal adults, whereas vitamin B 12 in meat appears to be less available [12] . Some foods may inhibit absorption of vitamin B 12 , whereas the gastric stimulation that a meal induces may enhance vitamin B 12 absorption. Because free crystalline vitamin B 12 can attach to food binders in vitro [13] , such attachment of free vitamin B 12 from a supplement when taken together with food is theoretically possible. Better understanding of all these diverse influences can help guide fortification choices as well as decide if supplements are better taken on an empty stomach. a. Data are combined from different studies, using as sources Berlin et al. [5] and compilations in Chanarin's textbook [6] . Some dose levels were studied for only one of the absorption categories of patients. The table is modified from Carmel [52] . SI conversion for vitamin B 12 : 1 μg = 0.74 nmol. b. In normal persons, both specific saturable absorption and passive nonsaturable diffusion operate normally. The percentage that is absorbed specifically via IF declines as the oral dose increases because the capacity of IF-mediated absorption is finite, and fixed passive diffusion becomes an increasing contributor to the total absorption when the oral dose reaches 50 μg (at which 0.5 μg is absorbed nonspecifically -see "Absence of IF" columnthus presumably contributing one-third of the total 1.5 µg amount shown in the "Normal absorption" column). c. When IF is absent, absorption is limited to passive, nonsaturable diffusion only. These values were obtained from a different study from those in the column for normal subjects. Comparability may be limited. therefore, but the patterns illustrate the essential points.
(The data presumably apply equally to patients with intestinal diseases that prevent uptake of IF.) d. Data are not available for food-vitamin B 12 malabsorption, but the vitamin B 12 bioavailability probably lies between those in the normal state and in the absence of IF. S180 R. Carmel
Concepts of vitamin B 12 deficiency relevant to fortification

Classical clinical vitamin B 12 deficiency is serious but uncommon
Clinically expressed vitamin B 12 deficiency accounts for only a small fraction, probably < 10%, of all vitamin B 12 deficiencies. It usually arises from diseases in which gastric IF is absent or the IF cannot be taken up in the ileum [14] . The main example, pernicious anemia, is a disease defined by the loss of IF secretion. The severity of clinical deficiency, its origin in chronic and often irreversible gastroenterological diseases, and its usually relentless progression over a few years necessitate treating it as a purely medical issue with focused medical intervention. Treatment must often be lifelong and requires monthly injection or daily oral doses of 1,000 µg vitamin B 12 .
Subclinical vitamin B 12 deficiency has uncertain health implications
Unlike clinically obvious vitamin B 12 deficiency, mild, usually purely biochemical vitamin B 12 deficiency ("subclinical deficiency") is very common. It affects 10% to 25% of the elderly, depending on the criteria applied, and accounts for > 90% of all vitamin B 12 deficiency [2, 15] . It is, almost by definition, an asymptomatic state [1] , and has parallels with subclinical, nonanemic iron deficiency expressed solely by variably diminished iron stores and ferritin levels. Especially importantly, subclinical vitamin B 12 deficiency has a different spectrum of causes, many of them still unidentified, as compared with clinical deficiency [1, 2, 15] . About 30% to 40% of cases are associated with malabsorption limited to food-vitamin B 12 [8] , and variable but unspecified proportions are due to poor intake [2] . As a result of these IF-unrelated causes, progression of subclinical deficiency is often very slow [2, 15] . Transformation of subclinical into clinically expressed deficiency is uncommon even after a decade, and even the biochemical abnormalities themselves often remain stationary or reverse spontaneously [2, 16, 17] . Fortification with vitamin B 12 may have its major impact on subclinical deficiency, which accounts for most of the new influx of cases of vitamin B 12 deficiency and which usually arises from nonmalabsorptive or weakly malabsorptive causes. So little is known about the direct effects of subclinical deficiency on health that its course, prognosis, and the need for therapy remain matters of opinion rather than fact. Subclinical neurocognitive and electrophysiological changes of undetermined impact have sometimes been noted [18] [19] [20] . Health consequences are unproven but remain conceivable even in the subclinical state, perhaps especially in susceptible subpopulations such as children.
Geographic and demographic characteristics of vitamin B 12 deficiency
For a long time, vitamin B 12 deficiency was viewed strictly through the clinical prism and therefore was thought to be geographically limited to northern European populations where pernicious anemia is most common, and in regions such as the Indian subcontinent, where dietary intake of cobalamin is limited for religious reasons and diseases such as tropical sprue are endemic [6] . However, high rates of deficiency have been described in developing countries in South and Central America and Africa as well as China in recent years. The elderly appear to be the most susceptible group, but deficiency is not limited to them. Two points are noteworthy about all these reports. First, the vitamin B 12 deficiency, when actually characterized, seems overwhelmingly to be subclinical in nature. Second, the deficiency is often ascribed to poor intake, but despite often limited diets, such attribution may be premature because absorption was rarely tested. Unrecognized malabsorption, including such subtle possibilities as mild tropical sprue [21] and various infectious processes, may need evaluation in some regions.
Concepts of vitamin B 12 bioavailabilities relevant to fortification Comparison with the folic acid model
Fortification of cereals and grain products with folic acid has proven moderately effective in its stated goal of reducing the incidence of neural tube defects (NTD), and even more effective in improving folate status [22] . The levels of folic acid fortification, which some argue should be higher so as to reduce NTD risk even more, were restricted primarily out of concern that high doses could contribute to neurologic complications in vitamin B 12 -deficient patients. Two scenarios have been suggested for such complications. Folic acid often mitigates the anemia of vitamin B 12 deficiency and, by delaying the latter's diagnosis, may allow its neurologic defects to progress [6] . Alternatively, anecdotal but never disproven reports suggested that high doses of folic acid may accelerate neurologic deterioration directly in some (perhaps especially susceptible) cases. Proposals were made, therefore, to cofortify food with vitamin B 12 , so as to treat unrecognized vitamin B 12 deficiency and reduce such risks.
Data relevant to vitamin B 12 fortification remain scarce, and no country has yet mandated vitamin B 12 fortification. Several advisory panels have offered fortification recommendations ranging between 1 µg S181 Vitamin B 12 fortification vitamin B 12 /day and 10 µg vitamin B 12 /100 g grain product [4, 23] . The bases for the recommendations were not detailed and appear not to have fully taken into account the likelihood that persons at greatest risk for vitamin B 12 deficiency would probably also absorb the least vitamin B 12 , a problem not seen in folic acid fortification.
In fact, vitamin B 12 differs from the folic acid fortification model in bioavailability, absorption characteristics, and other important features in so many ways that vitamin B 12 fortification plans require different and sometimes opposite assumptions than folic acid fortification plans (table 2). As table 1 illustrates, even when absorption is normal, very limited bioavailability rates characterize all but the smallest vitamin B 12 doses. In cases of malabsorption involving disruption of IF secretion or intestinal IF uptake, the amount of vitamin B 12 from meals or supplements that can be absorbed is negligible (< 1 µg) until intake approaches 100 µg. The amounts absorbed frequently cannot meet even the recommended dietary allowance of 2.4 µg [24] , let alone replenish depleted stores.
Folate is absorbed much better than vitamin B 12 in both health and disease. Absorption of reduced, polyglutamated folates in a meal by specific, saturable, carrier-mediated processes approaches 50% when amounts up to 200 µg are eaten. In the most telling contrast with vitamin B 12 , the lowest bioavailability of unreduced folic acid is calculated to be 85% from fortified food and approaches 100% by nonspecific, unlimited absorption when taken as a supplement [25] [26] [27] . The high absorption ensures that oral folic acid can be effective even in the relatively small minority of persons with folate malabsorption [6, 28] . Fortification with vitamin B 12 is unlikely to be as effective as folic acid fortification, especially in those persons who need it the most.
Limited responsiveness to oral vitamin B 12 despite intact IF-mediated absorption
As discussed in the previous section and illustrated in table 1, absorption of both free (crystalline) and [29, 30] . Prospective controlled studies subsequently demonstrated that biochemical responses to supplementation were very often incomplete in elderly persons, even without gastric surgery (table 3) [31] [32] [33] . Substantive biochemical improvement did not occur in many cases until oral doses of 500 µg or greater were used [33] . Such doses resemble the oral 1,000-to 2,000-µg vitamin B 12 doses required to treat patients with pernicious anemia and other diseases with failure of the IF system [5, 6] . These unexplained but consistent observations suggest that small, heretofore standard oral doses [2, [15] [16] [17] . Second, the decision to dispense with untreated control groups surrendered the opportunity to document the extent of the spontaneous improvement that often occurs. Claiming ethical constraints may set disabling precedents against controlled studies of subclinical deficiency in the future. d. The table emphasizes the studies' findings in individuals. The analytic emphasis on mean group values and outcomes in all three papers paralleled the failure to examine the nonresponders to the various doses to determine why they did not respond: Were the nonresponders not cobalamin-deficient? Did they have malabsorption? Were there other reasons? e. The small number of subjects in the study may account for the borderline significance. f. Even at vitamin B 12 doses of 1,000 μg, however, MMA levels remained abnormal in 24% of cases. S183 Vitamin B 12 fortification approximating the vitamin B 12 content of 2 to 6 µg in multivitamin pills in the United States should no longer be used for targeted supplementation. They further suggest that large doses must be used in fortification schemes and that existing recommendations of amounts of 1 to 10 µg will be ineffective. Although published surveys, not cited here, consistently report improved biochemical vitamin B 12 status in populations given small or moderate oral vitamin B 12 supplements, the reliance of these studies on mean values and group statistics can often hide subsets of persons with little or no improvement within the overall associations of supplementation and better biochemical status. Healthneutral raisings of already normal serum vitamin B 12 levels (e.g., 400 ng/L rising to 600) can mathematically mask the more relevant failures of some low levels to improve. Moreover, the poor responders were usually not studied further, as evident in all three studies in table 3, none of which examined the causes of the poor responsiveness. It will be important to identify whether food-vitamin B 12 malabsorption is the sole culprit, as assumed from the poor responsiveness after gastric surgery [29, 30] ; a recent study purporting to show responsiveness of patients with food-vitamin B 12 malabsorption to very small oral doses of vitamin B 12 [34] must be discounted because its diagnostic criteria for malabsorption were not credible [35] .
Design and evaluation of an appropriate vitamin B 12 fortification model
Information, planning, and decisions in at least four areas are needed to design a viable vitamin B 12 fortification plan. Unfortunately, much of the needed information on which to base such decisions is missing. The four issues are summarized next and rest in large part on the background information discussed in the preceding sections.
Defining the goal of vitamin B 12 fortification
The precise objective must be clearly defined. In the case of folic acid fortification, the stated goal was reducing the risk of NTD, not the elimination of folate deficiency, which was more readily achieved [22] . Although convincing evidence of the health benefits of vitamin B 12 fortification does not yet exist, several plausible goals have been suggested. Most of them are linked to prevention or amelioration of the mild, usually subclinical vitamin B 12 deficiency that affects large segments of populations worldwide. Mild or subclinical deficiency is common, is usually accompanied by either normal absorption or by food-vitamin B 12 malabsorption, usually has a slow, often variable progression, and generally appears not to require urgent intervention. It seems a more viable public health target than clinical vitamin B 12 deficiency, which is infrequent, is typically due to malabsorption based on failure of the IF system, progresses relentlessly if not treated correctly, and must be viewed as a medical disease requiring individualized medical intervention.
Vitamin B 12 fortification may help prevent progression of subclinical deficiency to clinical deficiency, but the risk and rate of such progression have never been determined, and in fact appear to be low [15] [16] [17] . Whether reversal of either the vitamin B 12 -related biochemical abnormalities or the subclinical neurologic and electrophysiologic abnormalities that appear to accompany some cases of subclinical deficiency has any direct health benefits also needs to be determined. Neither the postulated direct linkages of subclinical deficiency to osteopenia, cognitive dysfunction, and other long-term effects nor the reversal of the latter conditions by vitamin B 12 fortification have yet been proven. Separate studies are also needed to determine whether subclinical vitamin B 12 deficiency poses any special health or developmental risks for young children.
Reducing homocysteine levels is a potential ancillary goal of vitamin B 12 fortification, as vitamin B 12 status is a major determinant of homocysteine levels in the elderly [36] . Treating subclinical vitamin B 12 deficiency contributes to homocysteine reduction, but the benefits of doing so for the vascular complications linked epidemiologically with hyperhomocysteinemia are proving disappointing [37] .
A goal strongly advocated by some has been to improve vitamin B 12 status in order to lessen the possible risk of neurologic complications posed by high folate intake in persons with unrecognized and untreated vitamin B 12 deficiency. The hope has also been expressed that doing so will remove a major barrier to higher levels of folic acid fortification. The sporadic neurological risk is an issue that continues to be debated [38, 39] but cannot be resolved because of ethical constraints on prospective studies. Whatever risk folic acid poses for adverse neurological consequences is probably more relevant to persons whose vitamin B 12 deficiency arises from classical, severely malabsorptive diseases, such as pernicious anemia. Such persons, however, may not be helped by vitamin B 12 fortification because they are typically unresponsive to all but extremely high doses of oral vitamin B 12 (e.g., 1,000 µg) or to injections. It is unknown whether fortification provides any neurologic protection in subclinical deficiency either. The latter appears to be irregularly and slowly progressive at best and has given little evidence of being an incubator of folate-mediated neurological progression.
No goals have been identified to date for vitamin B 12 fortification in possible nutrient-gene interac-S184 R. Carmel tions, including augmentation of the reduction of NTD risks.
Unresolved questions and gaps in evidence of benefit surround all of the mentioned goals for vitamin B 12 fortification. The possibility of an accumulation of several proven benefits, even if each is small, also merits consideration and could constitute a cogent argument for increasing vitamin B 12 intake, but such benefits and effectiveness may be hard to prove or monitor.
Methodological considerations
As discussed earlier, vitamin B 12 fortification raises more varied and complex details and problems of bioavailability and absorption than does folic acid fortification. A review of the modeling, testing, monitoring, and adjustments used to establish folic acid fortification in the United States in the 1990s [22] noted that cofortification with vitamin B 12 was not recommended at that time because dietary intake data collected in 1965 and reported in 1974 [40] found that vitamin B 12 intake was generally above recommended levels. As a result, vehicle suitability and stability testing was not done. The only data relevant to fortification with vitamin B 12 were obtained with ready-to-eat breakfast cereals and showed, on average, 17% loss of vitamin B 12 during production and 4% to 17% losses after storage for 6 to 12 months [41] .
Cereals and grains are thought to be the most practical fortification vehicle from many standpoints and are used for folic acid and iron fortification in many countries. Data on compatibility and interactions between vitamin B 12 and these two nutrients are not available. Dairy products, such as milk, are unsuitable vehicles because they will not be accepted by many vegetarians, who are a key target. Various juices might be considered, especially if they are shown to lack protein binders of vitamin B 12 , and could also prove practical should infants need fortified foods. Whatever the chosen vehicle, testing of the bioavailability of vitamin B 12 added to the vehicle, and subsequent monitoring, need to be conducted individually within each of several target subgroups, such as persons with and without known food-vitamin B 12 malabsorption, children, and the elderly.
The most critical issue arises from the new evidence that effective fortification may need to provide massive concentrations of vitamin B 12 of 500 µg or more daily [33] in order to affect most of the persons meant to benefit from it. The possibility of adverse effects of such huge daily doses over the long term will need to be considered, because such amounts will simultaneously expose huge numbers of nondeficient persons to daily vitamin B 12 intakes several hundred times greater than the recommended dietary allowance. Interaction of the high vitamin B 12 concentrations with other added or intrinsic nutrients in the fortified food will also need to be examined, as will the technical feasibility of such scales of vitamin B 12 fortification, including such seemingly trivial issues as the very deep-pink color that such high vitamin B 12 concentrations may impart to the vehicle. Finally, cyanocobalamin, the usual form in supplements, is assumed to be the optimal form for fortification. Isotopic studies at oral doses up to 50 µg suggest that cyanocobalamin and hydroxocobalamin are the best-absorbed cobalamins [7, 42] .
Safety issues of vitamin B 12 fortification
Vitamin B 12 has few known toxicities, and they are uncommon. Allergic or immune reactions occur rarely with parenteral vitamin B 12 therapy, and even more rarely with oral vitamin B 12 .
By far the most serious problem of mandatory fortification is the conundrum that persons who are not vitamin B 12 -deficient and do not need vitamin B 12 typically absorb it much more efficiently than most persons with deficiency, who actually need the vitamin B 12 . If the higher fortification doses are chosen, nondeficient persons are likely to accumulate especially large amounts on top of their preexisting normal stores. The lifelong daily intake of 500 µg or more of vitamin B 12 by healthy, nondeficient persons may increase tissue stores in children and adults considerably beyond existing norms.
Adverse effects of high tissue levels seem unlikely, but data are lacking about chronically high levels. The use of cyanocobalamin in fortification raises additional theoretical concerns about its long-term accumulation in such high concentrations. Cyanocobalamin is not a physiological form and normally comprises only 2% of cobalamins in plasma and 6% in red blood cells [6] . However, cyanocobalamin reportedly accounted for 48% of the plasma cobalamins and 17% of red cell cobalamins in patients taking 1,000 µg of cyanocobalamin orally daily for years [43] . Those findings indicate that much oral cyanocobalamin is absorbed unchanged and gains access to cells in its unconverted and unphysiological state. Whether cellular accumulation of cyanide also occurs over the long term is unknown.
Other effects have been hypothesized and merit exploration. The elaborate transport protein system for vitamin B 12 [44] seems designed to limit the access of nonfunctional and perhaps harmful vitamin B 12 analogs to tissues, but does not eliminate them entirely. Exclusionary processes may be overwhelmed or bypassed when high vitamin B 12 doses are used regularly. Studies of multivitamin-mineral supplements indicate that other vitamins and some minerals may enhance conversion of cyanocobalamin to such analogs [45] . It is unknown whether increased analog formation from vitamin B 12 takes place in tissues with unusually high concentrations of vitamin B 12 , nor has S185 Vitamin B 12 fortification toxicity from analogs been proven yet.
Transcobalamin I (haptocorrin), a vitamin B 12 -binding protein originating in granulocytes and secretory glands, may have unspecified antimicrobial activity, perhaps by binding vitamin B 12 and thus denying microbial access to it [44] . It has been hypothesized that this protective mechanism might be circumvented by the accumulation of vitamin B 12 , much as iron accumulation seems to increase the risk of microbial infection. The increased daily concentrations of vitamin B 12 in the gut could theoretically also facilitate increased gastric or intestinal bacterial growth.
Although the adverse possibilities mentioned in this section are not proven, the slow turnover of vitamin B 12 stores [6] suggests that reversal could take a long time should vitamin B 12 excess prove to have any unwanted effects. Folic acid, in contrast, has a more rapid turnover.
Monitoring of vitamin B 12 fortification
Pilot trials are needed before instituting mandatory fortification because of the gaps in information on many of the unknown issues, including basic things such as the proper dose. Effectiveness can be judged by improvement of serum vitamin B 12 levels and, more importantly, of methylmalonic acid or homocysteine levels. The targeted benefits that motivated instituting fortification would also need to be monitored.
It is important that analysis of the outcomes not limit itself to changes in mean levels and overall statistical trends alone, as is too often done but which can obscure small but critical subgroups of responders or nonresponders. A basic monitoring need is to focus its attention on effectiveness or lack of it in the targeted subgroups of interest, such as persons with low vitamin B 12 levels, persons with known food-vitamin B 12 malabsorption, vegetarians, the elderly, and children, as well as in control groups with neither deficiency nor malabsorption. Possible adverse effects should similarly be examined in important subgroups, especially in nondeficient persons with vitamin B 12 levels or stores in the upper quartiles, children, and the elderly. Levels of cyanocobalamin and analogs and changes in infection patterns are sources of theoretical toxicity that may warrant monitoring.
Vitamin B 12 supplementation
The assumption that the case for mandatory vitamin B 12 fortification is self-evident is not justified because the health benefits of population-wide intervention are not clear. The predominantly subclinical deficiency of vitamin B 12 , unlike the uncommon clinical deficiency, has uncertain health consequences and natural history [2, 15, 17] . Benefits of vitamin B 12 for NTD prevention are unclear, and the effectiveness of vitamins in reducing vascular disease by reducing mild hyperhomocysteinemia is proving disappointing. Therefore, the case for mandatory vitamin B 12 fortification is less compelling than was the case for folic acid fortification to reduce the risk of NTD, in addition to being more difficult to achieve successfully.
Given the aforementioned uncertainties about fortification, vitamin B 12 supplementation aimed at selected population subgroups and individuals at high risk may prove a better, more practical goal. The shortcomings of supplementation programs, which are all voluntary, are well known too. Compliance is poor, and people who do not need supplements are often more likely to take them than those who do. However, vitamin B 12 supplementation could target the subgroups more likely to benefit, allow greater flexibility in dosages, and minimize exposure of the remaining population to massive increases in vitamin B 12 intake and accumulation. Even though the health benefits of vitamin B 12 supplementation remain to be proven in subclinical deficiency [15] , the most logical targets for supplementation efforts in every country would be the elderly, who harbor the highest prevalence of vitamin B 12 deficiency [46] ; vegetarians, who often have subclinical deficiency [47, 48] and are at higher risk for clinical deficiency whenever other, often malabsorptive disorders supervene; and nursing mothers who are vitamin B 12 -deficient and their newborns, because even if the mothers are only subclinically deficient, the infants may acquire potentially catastrophic neurologic and developmental complications if they are fed maternal breastmilk exclusively [49, 50] .
In countries with embedded societal predispositions and notably high rates of vitamin B 12 deficiency, such as India [47, 51] , unique cost-benefit calculations may be such as to better justify fortification than in other countries.
